



Noctiva (desmopressin acetate) Nasal Spray
Effective February 1, 2020

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Noctiva is a vasopressin analog nasal spray used in the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void.

Coverage Guidelines

Members may be approved when the following criteria has been met:

- The Member is diagnosed with nocturia due to nocturnal polyuria
- The Member is ≥ 50 years of age
- The prescriber is a urology specialist or consult notes are provided **AND**
- one of the following:
 - The member has had an inadequate response or adverse reaction to desmopressin acetate tablets; **or**
 - Clinical rationale is submitted why desmopressin acetate tablets are not appropriate

Continuation of Therapy

Reauthorizations will be granted upon receipt of current clinical information documenting effectiveness.

Limitations

1. Initial approvals will be granted for 3 months.
2. Reauthorizations will be granted for 12 months

References

1. DDAVP (desmopressin acetate) nasal spray [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; September 2018



2. DDAVP Tablets (desmopressin) [product monograph]. North York, Ontario: Ferring; December 2015
3. Andersson KE, Longstreth J, Brucker BM, et al. Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. *Pharm Res* 2019; 36:92
4. Ebell MH, Radke T, Gardner J. A systematic review of the efficacy and safety of desmopressin for nocturia in adults. *J Urol* 2014; 192:829

Review History

09/24/18 – Reviewed

11/18/2020- Reviewed by P&T

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.